CoChat

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

Open access
Sabari, Joshua K., Velcheti, Vamsidhar, Shimizu, Kazuhide, Strickland, Matthew R., Heist, Rebecca S., Singh, Mohini, Nayyar, Naema, Giobbie-Hurder, Anita, Digumarthy, Subba R., Gainor, Justin F., Rajan, Anant P., Nieblas-Bedolla, Edwin, Burns, Aaron C., Hallin, Jill, Olson, Peter, Christensen, James G., Kurz, Sylvia C., Brastianos, Priscilla K., Wakimoto, Hiroaki · 2022 · Clinical Cancer Research

Published version of a preprint

Cited by 135

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Purpose: Patients with KRAS-mutant non–small cell lung cancer (NSCLC) with brain metastases (BM) have a poor prognosis. Adagrasib (MRTX849), a potent oral small-molecule KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state. Adagrasib has been optimized for favorable pharmacokinetic properties, including long half-life (∼24 hours), extensive tissue distribution, dose-dependent pharmacokinetics, and central nervous system penetration; however, BM-specific antitumor activity of KRASG12C inhibitors remains to be fully characterized. Experimental Design: A retrospective database query identified patients with KRAS-mutant NSCLC to understand their propensity to develop BM. Preclinical studies assessed physiochemical and pharmacokinetic properties of adagrasib. Mice bearing intracranial KRASG12C-mutant NSCLC xenografts (LU99-Luc/H23-Luc/LU65-Luc) were treated with clinically relevant adagrasib doses, and levels of adagrasib in plasma, cerebrospinal fluid (CSF), and brain were determined along with antitumor activity. Preliminary clinical data were collected from 2 patients with NSCLC with untreated BM who had received adagrasib 600 mg twice daily in the phase Ib cohort of the KRYSTAL-1 trial; CSF was collected, adagrasib concentrations measured, and antitumor activity in BM evaluated. Results: Patients with KRAS-mutant NSCLC demonstrated high propensity to develop BM (≥40%). Adagrasib penetrated into CSF and demonstrated tumor regression and extended survival in multiple preclinical BM models. In 2 patients with NSCLC and untreated BM, CSF concentrations of adagrasib measured above the target cellular IC50. Both patients demonstrated corresponding BM regression, supporting potential clinical activity of adagrasib in the brain. Conclusions: These data support further development of adagrasib in patients with KRASG12C-mutant NSCLC with untreated BM. See related commentary by Kommalapati and Mansfield, p. 3179

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-22-0383

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 22

  1. Dinu, 2014, Prognostic significance of KRAS gene mutations in colorectal cancer–preliminary study, J Med Life, 7, 581
  2. Offin, 2019, Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers, Cancer, 125, 4380, 10.1002/cncr.32461 · DOI
  3. Liu, 2019, Management of brain metastases: history and the present, Chin Neurosurg J, 5, 1, 10.1186/s41016-018-0149-0 · DOI
  4. Mehta, 2003, Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases, J Clin Oncol, 21, 2529, 10.1200/JCO.2003.12.122 · DOI · Paper page
  5. Cui, 2020, Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer, Lung Cancer, 146, 310, 10.1016/j.lungcan.2020.06.030 · DOI · Paper page
  6. Wu, 2021, Clinical and imaging features of non-small cell lung cancer with G12C KRAS mutation, Cancers, 13, 3572, 10.3390/cancers13143572 · DOI · Paper page
  7. Sebastian, 2021, KRAS G12C-mutated advanced non-small cell lung cancer: a real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315), Lung Cancer, 154, 51, 10.1016/j.lungcan.2021.02.005 · DOI · Paper page
  8. Lee, 2019, The impact of systemic treatment on brain metastasis in patients with non-small-cell lung cancer: a retrospective nationwide population-based cohort study, Sci Rep, 9, 18689, 10.1038/s41598-019-55150-6 · DOI
  9. Bauer, 2020, Brain penetration of lorlatinib: cumulative incidences of CNS and non-CNS progression with lorlatinib in patients with previously treated ALK-positive non-small-cell lung cancer, Target Oncol, 15, 55, 10.1007/s11523-020-00702-4 · DOI
  10. Soffietti, 2020, Management of brain metastases according to molecular subtypes, Nat Rev Neurol, 16, 557, 10.1038/s41582-020-0391-x · DOI · Paper page
  11. Ballard, 2016, Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity, Clin Cancer Res, 22, 5130, 10.1158/1078-0432.CCR-16-0399 · DOI · Paper page
  12. Kodama, 2014, Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases, Cancer Chemother Pharmacol, 74, 1023, 10.1007/s00280-014-2578-6 · DOI · Paper page
  13. Shaw, 2017, Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial, Lancet Oncol, 18, 1590, 10.1016/S1470-2045(17)30680-0 · DOI · Paper page
  14. Christensen, 2020, Targeting Kras(g12c) -mutant cancer with a mutation-specific inhibitor, J Intern Med, 288, 183, 10.1111/joim.13057 · DOI · Paper page
  15. Hu, 2018, Disease-causing mutations in the G protein galphas subvert the roles of GDP and GTP, Cell, 173, 1254, 10.1016/j.cell.2018.03.018 · DOI · Paper page
  16. Prentice, 1978, The analysis of failure times in the presence of competing risks, Biometrics, 34, 541, 10.2307/2530374 · DOI · Paper page
  17. Shimizu, 2022, Anatomy-oriented stereotactic approach to cerebrospinal fluid collection in mice, Brain Res, 1774, 147706, 10.1016/j.brainres.2021.147706 · doi:10.1016/j.brainres.2021.147706
  18. Kiyokawa, 2021, Modification of extracellular matrix enhances oncolytic adenovirus immunotherapy in glioblastoma, Clin Cancer Res, 27, 889, 10.1158/1078-0432.CCR-20-2400 · DOI
  19. Miller, 2008, Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy, Pharmacol Rev, 60, 196, 10.1124/pr.107.07109 · DOI · Paper page
  20. Janne, 2019, A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors
  21. Sanchez-Cespedes, 2002, Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung, Cancer Res, 62, 3659
  22. Shih, 2020, Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma, Nat Genet, 52, 371, 10.1038/s41588-020-0592-7 · DOI · Paper page

Cited by

See all 135

Metadata

Authors
Sabari, J. K., Velcheti, V., Shimizu, K., Strickland, M. R., Heist, R. S., Singh, M., Nayyar, N., Giobbie-Hurder, A., Digumarthy, S. R., Gainor, J. F., Rajan, A. P., Nieblas-Bedolla, E., Burns, A. C., Hallin, J., Olson, P., Christensen, J. G., Kurz, S. C., Brastianos, P. K., & Wakimoto, H.
Venue
Clinical Cancer Research
Published
2022-04-11
Volume
28
Issue
15
Pages
3318-3328
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W4223491316
Cited by
135
References
10
FWCI
15.36
Type
journal article
Language
en
Open access
hybrid
Funders
  • Mirati Therapeutics
  • National Institute of Health (5R01CA227156-02)
  • Damon Runyon Cancer Research Foundation
  • Ben and Catherine Ivy Foundation
  • Breast Cancer Research Foundation
  • Demetra fund of the Hellenic Women's Association
  • Terry and Jean de Gunzburg MGH Research Scholar Award

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-22-0383
The paper
Sabari, J. K., Velcheti, V., Shimizu, K., Strickland, M. R., Heist, R. S., Singh, M., Nayyar, N., Giobbie-Hurder, A., Digumarthy, S. R., Gainor, J. F., Rajan, A. P., Nieblas-Bedolla, E., Burns, A. C., Hallin, J., Olson, P., Christensen, J. G., Kurz, S. C., Brastianos, P. K., & Wakimoto, H. (2022). Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-22-0383

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.